About two years ago, Cerberus Capital Management agreed to buyout Talecris Biotherapeutics. So far, it looks like a winner.
In 2006, Talecris paid a $760 million dividend. Oh, and now the company has filed to go public.
Talecris is one of the largest producers and marketers of plasma-derived protein therapies. These therapies help to extend the lives of people who suffer from immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns.
Last year, the company posted revenues of $1.1 billion and net income of $87.4 million. Adjusted EBITDA was $264.1 million.
The roots of Talecris go back to the early 1940s and eventually became part of Bayer Healthcare (NYSE: BAY).
The underwriters on the IPO include Morgan Stanley (NYSE: MS), Goldman Sachs (NYSE: GS), and JPMorgan (NYSE: JPM). The proposed ticker symbol is "TLCR."
You can find the prospectus at the SEC website. Also, if you want to check out more recent IPO filings, click here.
Tom Taulli is the author of various books, including the Complete M&A Handbook and the EDGAR-Online Guide to Decoding Financial Statements.
Talecris IPO a winner for Cerberus Capital
Recent Posts
- Investors pressure private equity funds to cut fees (7/03/2009)
- Will an IPO bring more transparency to KKR? (7/02/2009)
- Will FDIC's new rules for buying failed banks deter private-equity investors (7/01/2009)
- Blackstone anticipates recovery in Europe (6/30/2009)
- Carlyle, KKR, JC Flowers and others eye Nan Shan Life (6/29/2009)
BloggingBuyouts is provided for informational purposes only. Nothing on the service is intended to provide personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio or securities, transaction, investment strategy or other matter. You are solely responsible for any investment decisions that you make. The contributors who provide the content of BloggingBuyouts may, from time to time, hold positions in the securities discussed at the time of writing and they may trade for their own accounts. Such holdings will be disclosed at the time of writing. By using the site, you agree to abide to BloggingBuyouts' Terms of Use.
